Future of Personalized Medicine in Non-Small-Cell Lung Cancer
Department of Oncology, McGill University Health Centre, Montreal, QC, Canada
Curr. Oncol. 2012, 19(s1), 86; https://doi.org/10.3747/co.19.1049
Submission received: 8 March 2012
/
Revised: 5 April 2012
/
Accepted: 2 May 2012
/
Published: 1 June 2012
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The remarkable progress we are witnessing in the understanding of the molecular biology and signalling pathways of non-small-cell lung cancer (NSCLC) cells has resulted in ErbB-targeted therapies and many other targeted agents, especially Alk inhibitors, now in clinical trials [...]
Share and Cite
MDPI and ACS Style
Hirsh, V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Curr. Oncol. 2012, 19, 86. https://doi.org/10.3747/co.19.1049
AMA Style
Hirsh V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Current Oncology. 2012; 19(s1):86. https://doi.org/10.3747/co.19.1049
Chicago/Turabian StyleHirsh, V. 2012. "Future of Personalized Medicine in Non-Small-Cell Lung Cancer" Current Oncology 19, no. s1: 86. https://doi.org/10.3747/co.19.1049
